Observational studyBMC infectious diseases2026
Chronic comorbidities, concomitant medications, and treatment patterns of chronic hepatitis B patients receiving nucleos(t)ide analogue therapy: a hospital claims database study in Japan.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection poses a persistent public health challenge globally, with chronic cases often leading to severe liver diseases and associated comorbidities. In Japan, where the prevalence of chronic HBV remains substantial in the elderly population, the burden of comorbidities and polypharmacy in patients receiving nucleos(t)ide analogue (NUC) therapy is not well characterized. The aim of the present study was to evaluate the prevalence of chronic comorbidities and concomitant medication use in chronic hepatitis B (HBV) patients on NUC therapy in Japan.
methodsA retrospective, cross-sectional, observational study using a nationwide hospital claims database was conducted. Data were obtained from the Medical Data Vision (MDV) database, comprising 480 hospitals in Japan from 2008 to 2023. Patients with chronic HBV were defined by ICD-10 code plus NUC prescription for HBV; controls had no HBV-related diagnoses or NUC prescriptions. Controls were first selected 1:3 by same age, sex, and visit month, and then propensity score-matched to cases on age, sex, and hospital bed size (caliper 0.2).
resultsA total of 25,199 chronic HBV patients on NUC therapy were compared with 134,597 age- and sex-matched non-HBV patients using propensity score matching. Mean ages were 63.7 (SD 12.9) years and 64.3 (SD 15.8) years, respectively; 59.2% and 54.0%, respectively, were male. Patients with chronic HBV had a significantly higher prevalence of comorbidities than non-HBV patients, including cancer (37% vs. 5.5%; difference 31.5% points, 95% confidence interval (CI) 30.8–32.2% points), hypertension (35.5% vs. 8.1%; difference 27.4% points, 95% CI 26.7–28.1% points), and diabetes mellitus (35.2% vs. 5.3%; difference 29.9% points, 95% CI 29.2–30.6% points). In patients aged 70 years or older, 64.8% had two or more chronic comorbidities, and 57.9% were prescribed more than one concomitant medication. The most common concomitant medications included drugs for acid-related disorders (28.1% vs. 0.2%; difference 27.9% points, 95% CI 27.3–28.5% points), agents acting on the renin-angiotensin system (11.8% vs. 0.0%; difference 11.8% points, 95% CI 11.4–12.2% points), and lipid-regulating agents (11.7% vs. 0.1%; difference 11.6% points, 95% CI 11.2–12.0% points).
conclusionsChronic HBV patients on NUC therapy in Japan have a substantial burden of comorbidities and polypharmacy, particularly among elderly patients. These findings suggest the need for careful age-specific management to reduce the potential impacts of comorbidities and polypharmacy in chronic HBV patients in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.